- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT05502341
Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (ARTISTRY-1) (ARTISTRY-1)
Une étude de phase 2/3, randomisée, ouverte, multicentrique et contrôlée par un traitement actif, homogène sur le plan opérationnel, pour évaluer l'innocuité et l'efficacité du bictégravir/lénacapavir par rapport à un régime de base stable chez des personnes virologiquement supprimées atteintes du VIH-1 suivant des schémas thérapeutiques complexes stables
The goal of this clinical study is to learn more about the effects of switching to the study drugs, bictegravir (BIC) plus lenacapavir (LEN), versus current therapy (Phase 2) and BIC/LEN fixed-dose combination (FDC) versus current therapy (Phase 3) in people living with HIV (PWH).
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Réel)
Phase
- Phase 2
- Phase 3
Contacts et emplacements
Lieux d'étude
-
-
-
Cape Town, Afrique du Sud, 7925
- Desmond Tutu Health Foundation Clinical Trials Unit
-
Ga-Rankuwa, Afrique du Sud, 208
- Sefako Makgatho Health Sciences University
-
Johannesburg, Afrique du Sud, 2193
- Ezintsha
-
-
-
-
-
Berlin, Allemagne, 10439
- zibp Zentrum für Infektiologie Berlin Prenzlauer Berg GmbH
-
Bonn, Allemagne, 53127
- Universitatsklinikum Bonn
-
Frankfurt, Allemagne, 60596
- Infektio Research GmbH & Co.KG
-
Hamburg, Allemagne, 20146
- ICH Study Center GmbH & Co. KG
-
München, Allemagne
- MVZ München am Goetheplatz
-
-
-
-
-
Buenos Aires, Argentine, 1202
- Fundación Huésped
-
Buenos Aires, Argentine, 1072
- Hospital General de Agudos J.M Ramon Mejia
-
Buenos Aires, Argentine, 1425
- Helios Salud
-
-
-
-
New South Wales
-
Darlinghurst, New South Wales, Australie, 2010
- St.Vincent's Hospital Sydney
-
Darlinghurst, New South Wales, Australie, 2011
- Taylor Square Private Clinic
-
Sydney, New South Wales, Australie, 2010
- Holdsworth House Medical Practice
-
-
Victoria
-
Melbourne, Victoria, Australie, 3004
- Alfred Health
-
-
-
-
-
Decarie Montreal, Canada, H4A 3J1
- Chronic Viral Illness Service / McGill University Health Centre (MUHC)
-
Montreal, Canada, H2L 0B1
- Clinique Medicale du Quartier Latin
-
Ottawa, Canada, K1H 8L6
- The Ottawa Hospital - General Campus
-
Regina, Canada, S4P 0W5
- ID Clinic
-
Toronto, Canada, M5G 1K2
- Maple Leaf Research
-
Vancouver, Canada, V6Z 2T1
- Spectrum Health
-
-
-
-
-
Daegu, Corée du Sud, 41944
- Kyungpook National University Hospital
-
Daejeon, Corée du Sud, 35015
- Chungnam National University Hospital
-
Seoul, Corée du Sud, 06591
- The Catholic University of Korea Seoul St. Mary's Hospital
-
Seoul, Corée du Sud, 03722
- Yonsei University Severance Hospital
-
-
-
-
-
Barcelona, Espagne, 08036
- Hospital Clinic Provincial de Barcelona
-
Madrid, Espagne, 28040
- Hospital Clinico San Carlos
-
Madrid, Espagne, 28046
- Hospital Universitario La Paz
-
Madrid, Espagne, 28034
- Hospital Ramon y Cajal, Madrid
-
Seville, Espagne, 4103
- Hospital Universitario Virgen del Rocio
-
-
-
-
-
Nice, France, 6202
- CHU Nice-Hôpital l'Archet
-
Paris, France, 75010
- Hospital Saint Louis
-
Paris, France, 75018
- Groupe Hospitalier Bichat Claude Bernard
-
Paris, France, 75651
- Höpital de la Pitié Salpêtrière
-
-
-
-
-
Milan, Italie, 20157
- ASST Fatebenefratelli Sacco
-
Milan, Italie, 20127
- IRCCS Ospedale San Raffaele
-
Modena, Italie, 40124
- Azienda Ospedaliero-Universitaria di Modena
-
Roma, Italie, 00149
- Istituto Nazionale Malattie Infettive "Lazzaro Spallanzani" IRCCS
-
Torino, Italie, 10149
- ASL Città di Torino
-
-
-
-
-
Nagoya, Japon
- National Hospital Organization Nagoya Medical Center
-
Osaka, Japon, 540-0006
- National Hospital Organization Osaka National Hospital
-
Tokyo, Japon, 162-0052
- Center Hospital of the National Center for Global Health and Medicine
-
-
-
-
PR
-
San Juan, PR, Porto Rico, 00909
- Hope Clinical Research
-
San Juan, PR, Porto Rico, 00935
- Proyecto ACTU
-
-
-
-
-
Birmingham, Royaume-Uni, B9 5SS
- Department of HIV & Sexual Medicine
-
Brighton, Royaume-Uni, BN2 3EW
- Brighton and Sussex University Hospitals NHS Trust
-
London, Royaume-Uni, E1 1BB.
- Barts Health NHS Trust
-
London, Royaume-Uni, SE5 9RS
- HIV medicine and infectious diseases
-
London, Royaume-Uni, SW109NH
- St.Stephen's AIDS Trust, Clinical Trials Unit, 1st Floor, St.Stephen's Centre
-
-
-
-
-
Santo Domingo, République Dominicaine
- Instituto Dominicano de Estudio Virologicos - IDEV
-
-
-
-
-
Kaohsiung City, Taïwan, 80756
- Kaohsiung Medical University Chung-Ho Memorial Hospital
-
Kaohsiung City, Taïwan, 81362
- Kaohsiung Medical University Chung-Ho Memorial Hospital
-
New Taipei City, Taïwan, 22060
- Far Eastern Memorial Hospital
-
Taoyuan City, Taïwan, 33004
- Taoyuan General Hospital
-
-
-
-
California
-
Berkeley, California, États-Unis, 48072
- Be Well Medical Center
-
Beverly Hills, California, États-Unis, 90211
- Pacific Oaks Medical Group
-
Los Angeles, California, États-Unis, 90036
- Ruane Clinical Research Group, Inc
-
Oakland, California, États-Unis, 94609
- Alta Bates Summit Medical Center, Summit Campus, East Bay Advanced Care
-
Palm Springs, California, États-Unis, 92262
- Bios Clinical Research
-
San Diego, California, États-Unis, 92103
- University of California San Diego (UCSD)
-
Torrance, California, États-Unis, 90502
- Lundquist Institute for Biomedical Innovation at Harbor - UCLA Medical Center
-
West Hollywood, California, États-Unis, 90046
- The Men's Health Foundation
-
-
Colorado
-
Denver, Colorado, États-Unis, 80204
- Denver Health Medical Center
-
-
Connecticut
-
New Haven, Connecticut, États-Unis, 06510
- Yale University; School of Medicine; AIDS Program
-
-
Florida
-
DeLand, Florida, États-Unis, 32720
- Midland Florida Clinical Research Center, LLC
-
Fort Lauderdale, Florida, États-Unis, 33316
- Gary Richmond, MD, PA, Inc.
-
Fort Lauderdale, Florida, États-Unis, 33308
- Therafirst Medical Centers
-
Ft. Pierce, Florida, États-Unis, 34982
- Midway Immunology & Research Center, LLC
-
Miami, Florida, États-Unis, 33136
- Schiff Center for liver Diseases/University of Miami
-
Miami Lakes, Florida, États-Unis, 33016
- Floridian Clinical Research
-
Orlando, Florida, États-Unis, 32803
- Orlando Immunology Center
-
Orlando, Florida, États-Unis, 32803
- Therapeutic Concepts, PA
-
West Palm Beach, Florida, États-Unis, 33407
- Triple O Research Institute PA
-
-
Georgia
-
Atlanta, Georgia, États-Unis, 30309
- Atlanta ID Group
-
Macon, Georgia, États-Unis, 31201
- Mercer University School of Medicine
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60613
- Howard Brown Health Center
-
-
Missouri
-
Kansas City, Missouri, États-Unis, 64111
- Kansas City Care Clinic
-
St Louis, Missouri, États-Unis, 63139
- Southampton Healthcare, Inc.
-
-
New Jersey
-
Newark, New Jersey, États-Unis, 07102
- Saint Michael's Medical Center
-
-
New Mexico
-
Santa Fe, New Mexico, États-Unis, 87505
- AXCES Research Group
-
-
New York
-
Flushing, New York, États-Unis, 11355
- New York Presbyterian Hospital
-
New York, New York, États-Unis, 10001
- Ricky K. Hsu, MD, PC
-
-
North Carolina
-
Chapel Hill, North Carolina, États-Unis, 27514
- University of North Carolina - Chapel Hill
-
Greenville, North Carolina, États-Unis, 27858
- East Carolina University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, États-Unis, 19107
- Philadelphia FIGHT
-
-
South Carolina
-
Charleston, South Carolina, États-Unis, 29425
- Medical University of South Carolina (MUSC) Research NEXUS
-
-
Texas
-
Austin, Texas, États-Unis, 78705
- Central Texas Clinical Research
-
Bellaire, Texas, États-Unis, 77401
- St. Hope Foundation
-
Dallas, Texas, États-Unis, 75246
- North Texas Infectious Diseases Consultants
-
Dallas, Texas, États-Unis, 75208
- AIDS Arms, Inc., DBA Prism Health North Texas
-
Fort Worth, Texas, États-Unis, 76104
- Texas Centers for Infectious Disease Associates
-
Houston, Texas, États-Unis, 77098
- Gordon E. Crofoot MD PA
-
Longview, Texas, États-Unis, 75605
- Diagnostic Clinic of Longview - Center for Clinical Research
-
-
Washington
-
Seattle, Washington, États-Unis, 98104
- Peter Shalit, MD
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Key Inclusion Criteria:
-
If plasma HIV-1 RNA measurements in the 6 months prior to screening are available, all levels must be < 50 copies/mL.
-
At least one documented plasma HIV-1 RNA level measured between 6 and 12 months (± 2 months) prior to screening. This and any other HIV-1 RNA measurements documented in this period must be < 50 copies/mL
-
Plasma HIV-1 RNA levels < 50 copies/mL at screening.
-
Currently receiving a complex antiretroviral (ARV) regimen due to previous viral resistance, or intolerance, or contraindication to existing single-tablet regimens (STR), and on this regimen for at least 6 months prior to the screening visit. The criteria to define a complex regimen in this study are as follows:
- A regimen containing a boosted protease inhibitor or a nonnucleos(t)ide reverse transcriptase inhibitor (NRTI) plus at least 1 other third agent (ie, an agent from a class other than NRTIs) (eg, bictegravir/emtricitabine/tenofovir alafenamide (coformulated; Biktarvy®)(BVY) + darunavir/cobicistat, BVY + etravirine), or
- A regimen of ≥ 2 pills/day, or a regimen requiring dosing more than once daily, or
- A regimen containing parenteral agent(s) (excluding a complete long-acting injectable regimen, such as intramuscular cabotegravir plus rilpivirine) as well as oral agents.
-
No documented or suspected resistance to bictegravir (BIC).
-
Estimated glomerular filtration rate ≥ 15 mL/min according to the Cockcroft-Gault formula for creatinine clearance (CLcr) who are not on renal replacement therapy.
Key Exclusion Criteria:
- Prior use of, or exposure to, lenacapavir (LEN)
- Active tuberculosis infection
- Chronic hepatitis B virus (HBV) infection
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Phase 2: Treatment Group 1: BIC 75 mg + LEN 25 mg
Participants will switch from their Stable Baseline Regimen (SBR) to a regimen of BIC 75 mg + LEN 25 mg, tablets administered orally once daily for up to 24 weeks. Participants will receive a 2-day pharmacokinetic (PK) oral loading dose of LEN 600 mg, on Days 1 and 2, in addition to the daily doses of BIC 75 mg + LEN 25 mg starting on Day 1. Participants who discontinue early or complete the Randomized Phase (RP) will have an option to continue in Extension Period (EP) |
Tablets administered orally without regard to food
Autres noms:
Tablets administered orally without regard to food
Autres noms:
|
|
Expérimental: Phase 2: Treatment Group 2: BIC 75 mg + LEN 50 mg
Participants will switch from their SBR to a regimen of BIC 75 mg + LEN 50 mg, tablets administered orally once daily for up to 24 weeks. Participants will receive a 2-day PK oral loading dose of LEN 600 mg, on Days 1 and 2, in addition to the daily doses of BIC 75 mg + LEN 50 mg starting on Day 1. Participants who discontinue early or complete the RP will have an option to continue in EP. |
Tablets administered orally without regard to food
Autres noms:
Tablets administered orally without regard to food
Autres noms:
|
|
Comparateur actif: Phase 2: Treatment Group 3: SBR
Participants will continue with their SBR for up to 24 weeks. Participants who discontinue early or complete the RP will have an option to continue in EP. |
SBR will include a combination of antiretroviral (ARV) regimen. ARV regimen may include the following, except for participants taking a single tablet regimen or taking a complete parenteral regimen (Cabenuva).
|
|
Expérimental: Phase 3: Treatment Group 1: BIC/LEN 75 mg/50 mg FDC
Participants will switch from their SBR to a regimen of BIC/LEN 75mg/50mg FDC, administered orally once daily for up to 48 weeks. Participants will receive a 2-day PK oral loading dose of LEN 600 mg, on Days 1 and 2, in addition to the daily doses of BIC/LEN 75 mg/50 mg FDC starting on Day 1. Participants who discontinue early or complete the RP will have an option to continue in EP. |
Tablets administered orally without regard to food
Autres noms:
|
|
Comparateur actif: Phase 3: Treatment Group 2: SBR
Participants will continue with their SBR for up to 48 weeks. Participants who will discontinue early or complete the RP had an option to continue in EP. |
SBR will include a combination of antiretroviral (ARV) regimen. ARV regimen may include the following, except for participants taking a single tablet regimen or taking a complete parenteral regimen (Cabenuva).
|
|
Expérimental: Phase 2/Phase 3:BIC/LEN 75/50 mg FDC
At the end of randomized treatment, participants in Phase 2 and Phase 3 treatment groups who discontinue early or complete the RP will be given an option to enter in EP and will receive BIC/LEN 75/50 mg FDC until the drug is available in market or Gilead elects to withdraw the study. Participants in the SBR groups (Phase 2 Treatment Group 3 and Phase 3 Treatment Group 2 will also receive a 2-day PK oral loading dose of LEN 600 mg, on Days 1 and 2 of EP). |
Tablets administered orally without regard to food
Autres noms:
Tablets administered orally without regard to food
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Phase 2: Percentage of Participants With Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) ≥ 50 Copies/mL at Week 24 as Determined by the United States Food and Drug Administration (US FDA) Defined Snapshot Algorithm
Délai: Week 24
|
Participants who had the last available on-treatment HIV-1 RNA≥ 50 copies/mL in the week 24 analysis window, or who did not have on-treatment HIV-1 RNA data in the week 24 analysis window and participants who discontinued study drug prior to or in the week 24 analysis window due to lack of efficacy, or who discontinued study drug prior to or in the week 24 analysis window due to adverse event (AE) or death and have the last available on-treatment HIV-1 RNA≥ 50 copies/mL, or who discontinued study drug prior to or in the week 24 analysis window due to reasons other than AE, death, or lack of efficacy and have the last available on-treatment HIV-1 RNA ≥ 50 copies/mL were included. The Week 24 window for snapshot algorithm was between Days 127 and 210 (inclusively). Percentages were rounded off. |
Week 24
|
|
Phase 3: Percentages of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Determined by the US FDA-defined Snapshot Algorithm
Délai: Week 48
|
Participants who had the last available on-treatment HIV-1 RNA ≥ 50 copies/mL in the Week 48 analysis window, or who did not have on-treatment HIV-1 RNA data in the Week 48 analysis window and who discontinued study drug prior to or in the Week 48 analysis window due to lack of efficacy, or who discontinued study drug prior to or in the Week 48 analysis window due to AE or death and have the last available on-treatment HIV-1 RNA ≥ 50 copies/mL, or who discontinued study drug prior to or in the Week 48 analysis window due to reasons other than AE, death, or lack of efficacy and have the last available on-treatment HIV-1 RNA ≥ 50 copies/mL were included. The Week 48 window for snapshot algorithm was between Days 295 and 378 (inclusively). Percentages were rounded off. |
Week 48
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Phase 2: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 as Determined by the US FDA-defined Snapshot Algorithm
Délai: Week 24
|
Participants who had the last available on-treatment HIV-1 RNA < 50 copies/mL in the Week 24 analysis window were included. The Week 24 window for snapshot algorithm was between Days 127 and 210 (inclusively). Percentages were rounded off. |
Week 24
|
|
Phase 2: Change From Baseline in Clusters of Differentiation 4 (CD4) Cell Count at Week 24
Délai: Baseline, Week 24
|
Baseline, Week 24
|
|
|
Phase 2: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) Through Week 24
Délai: First dose date up to Week 24
|
An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a study drug that did not necessarily had a causal relationship with the treatment. TEAEs were defined as any AE that begins on or after the date of first dose of study drug up to the date of last dose of study drug plus 60 days (for BIC+LEN or BIC/LEN FDC) or 30 days (for SBR) or any AE leading to study drug discontinuation. Percentages were rounded off. |
First dose date up to Week 24
|
|
Phase 2: PK Parameter: Cmax for Bictegravir (BIC) at Steady State
Délai: At Week 16 or 24
|
Cmax is defined as the maximum observed concentration of drug. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit. |
At Week 16 or 24
|
|
Phase 2: PK Parameter: Cmax for Lenacapavir (LEN) at Steady State
Délai: At Week 16 or Week 24
|
Cmax is defined as the maximum observed concentration of drug. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit. |
At Week 16 or Week 24
|
|
Phase 2: PK Parameter: AUCtau of BIC at Steady State
Délai: At Week 16 or 24
|
AUCtau is defined as the area under the concentration versus time curve over the dosing interval. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit. |
At Week 16 or 24
|
|
Phase 2: PK Parameter: AUCtau for LEN at Steady State
Délai: At Week 16 or Week 24
|
AUCtau is defined as the area under the concentration versus time curve over the dosing interval. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit. |
At Week 16 or Week 24
|
|
Phase 2: PK Parameter: Ctrough of BIC at Steady State
Délai: At Week 16 or Week 24
|
Ctrough is defined as the observed drug concentration at the end of the dosing interval. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit. |
At Week 16 or Week 24
|
|
Phase 2: PK Parameter: Ctrough of LEN at Steady State
Délai: At Week 16 or Week 24
|
Ctrough is defined as the observed drug concentration at the end of the dosing interval. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit. |
At Week 16 or Week 24
|
|
Phase 3: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Determined by the US FDA-defined Snapshot Algorithm
Délai: Week 48
|
Participants who had the last available on-treatment HIV-1 RNA < 50 copies/mL in the Week 48 analysis window were included. The Week 48 window for snapshot algorithm was between Days 295 and 378 (inclusively). |
Week 48
|
|
Phase 3: Change From Baseline in CD4 Cell Count at Week 48
Délai: Baseline, Week 48
|
An AE was any untoward medical occurrence in a clinical study participant administered a study drug that did not necessarily had a causal relationship with the treatment. TEAEs were defined as any AE that begins on or after the date of first dose of study drug up to the date of last dose of study drug plus 60 days (for BIC+LEN or BIC/LEN FDC) or 30 days (for SBR) or any AE leading to study drug discontinuation. Percentages were rounded off. |
Baseline, Week 48
|
|
Phase 3: Percentage of Participants Experiencing TEAEs Through Week 48
Délai: First dose date up to Week 48
|
An AE was any untoward medical occurrence in a clinical study participant administered a study drug that did not necessarily had a causal relationship with the treatment. TEAEs were defined as 1 or both of the following: Any AEs leading to premature discontinuation of study drug, or any AEs with an onset date on or after the study drug start date and no later than the last exposure date after permanent discontinuation of the study drug. Percentages were rounded off. |
First dose date up to Week 48
|
|
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 96 as Determined by the US FDA-defined Snapshot Algorithm
Délai: Week 96
|
Week 96
|
|
|
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 144 as Determined by the US FDA-defined Snapshot Algorithm
Délai: Week 144
|
Week 144
|
|
|
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96 as Determined by the US FDA-defined Snapshot Algorithm
Délai: Week 96
|
Week 96
|
|
|
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 144 as Determined by the US FDA-defined Snapshot Algorithm
Délai: Week 144
|
Week 144
|
|
|
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Change From Baseline in CD4 Cell Count at Week 96
Délai: Baseline, Week 96
|
Baseline, Week 96
|
|
|
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Change From Baseline in CD4 Cell Count at Week 144
Délai: Baseline, Week 144
|
Baseline, Week 144
|
|
|
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Percentage of Participants Experiencing TEAEs Through Week 96
Délai: Week 96
|
Week 96
|
|
|
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Percentage of Participants Experiencing TEAEs Through Week 144
Délai: Week 144
|
Week 144
|
Collaborateurs et enquêteurs
Parrainer
Publications et liens utiles
Publications générales
- Arora P, Hindman JT, West S, Ling J, Palaparthy R, Marathe DD. The effect of antacid and mineral supplements on bictegravir pharmacokinetics: results from a Phase 1, open-label, drug-drug interaction study. Antimicrob Agents Chemother. 2026 Jan 7;70(1):e0078125. doi: 10.1128/aac.00781-25. Epub 2025 Nov 28.
- Orkin C, Ruane PJ, Hedgcock M, Gaultier C, Losso MH, Trottier B, Lutz T, O'Reilly M, Bloch M, Slim J, Ramgopal M, Sokhela S, Mounzer K, Tsai HC, Santana Bagur J, Zhang X, Aizen K, Price K, Margot N, Montezuma-Rusca JM, Sklar P, Rhee M, Cahn P; ARTISTRY-1 Study Group. Switch to single-tablet bictegravir-lenacapavir from a complex HIV regimen (ARTISTRY-1): a randomised, open-label, phase 3 clinical trial. Lancet. 2026 Mar 28;407(10535):1249-1258. doi: 10.1016/S0140-6736(26)00307-7. Epub 2026 Feb 25.
- Ph2 PK data was included as part of the 2024 HIV-G presentation: https://hivglasgow.org/wp-content/uploads/2025/02/P049_Arora.pdf
Liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- GS-US-621-6289
- 2022-500929-33 (Autre identifiant: European Medicines Agency)
- DOH-27-052023-8574 (Autre identifiant: South African Clinical Trial Registry)
- jRCT2051230168 (Autre identifiant: Japan registry)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .